Short answer
Cullinan Therapeutics, Inc. (CGEM) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$54M
- +23.3% YoY · −8.1% QoQ
Source: XBRL data from the Cullinan Therapeutics, Inc. (CGEM) Q2 2026 10-Q on SEC EDGAR. USD.
Cullinan Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0; no product sales since inception
- R&D expenses $44.4M vs $61.0M YoY; G&A expenses $12.8M vs $14.8M
- Best R&D growth CLN-978, $10.5M vs $5.4M; worst CLN-619, $1.1M vs $7.3M
- Cash, equivalents and short-term investments $334.5M; operating cash use $84.3M vs $100.8M
- Funding runway at least twelve months; continued operating losses and additional capital needs expected
Risk Factors
- New risk: SRC loss triggered by non-affiliate market value exceeding $700 million on June 30, 2026
- Compliance burden: Large accelerated filer status begins January 1, 2027, requiring Section 404(b) auditor attestation
- Regulatory exposure: Untimely compliance could trigger SEC, stock-exchange sanctions, or investigations
- Operational impact: Expanded reporting requirements could divert management attention from business operations
- Financial risk: Higher legal, accounting, compliance, and investor-relations costs after December 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cullinan Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.